Table 3 Risk of prostate cancer death by use of anti-epileptic drugs with HDAC inhibitory properties compared to usage of other anti-epileptic drugs.
Risk of prostate cancer death | |||||||
|---|---|---|---|---|---|---|---|
HDACi AED use before diagnosis | HDAC use after diagnosis | ||||||
Number of PCa deaths/PCa cases | HR (95% CI)age adjusted | \({{{{{\mathbf{HR}}}}}}\,({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\) | Number of PCa deaths/PCa cases | HR (95% CI)age adjusted | \({{{{{\mathbf{HR}}}}}} ({{{{{\mathbf{95\%}}}}}} {{{{{\mathbf{CI}}}}}})_{{{{{{\mathbf{multivariable}}}}}}\; {{{{{\mathbf{adjusted}}}}}}^{\mathbf a}}\) | ||
Ever use of non-HDACi AED | 8/112 | Ref. | Ref. | Ever use of non-HDACi AED | 37/318 | Ref. | Ref. |
Ever use of HDACi AED | 33/227 | 2.66 (0.94–7.50) | 2.67 (0.81–8.77) | Ever use of HDACi AED | 27/343 | 0.50 (0.25–1.00) | 0.61 (0.31–1.23) |
Intensity of HDACi AED usage (DDDs per year) | |||||||
1st tertile | 10/75 | 2.36 (0.74–7.52) | 3.91 (1.07–14.22) | 1st tertile | 10/124 | 0.77 (0.28–2.12) | 1.27 (0.46–3.50) |
2nd tertile | 11/76 | 2.66 (0.85–8.34) | 1.70 (0.46–6.28) | 2nd tertile | 12/105 | 0.58 (0.24–1.43) | 0.56 (0.22–1.46) |
3rd tertile | 12/76 | 2.98 (0.96–9.23) | 3.31 (0.91–12.06) | 3rd tertile | 5/114 | 0.35 (0.13–0.89) | 0.46 (0.18–1.18) |
P for trend by tertile | 0.002 | 0.070 | P for trend by tertile | 0.002 | 0.048 | ||
